Table A2.

Estimated HR for Treatment Within Race Among Eligible Patients

Outcome	Race	No. of Patients	HR	95% CI	P
DFS	White	308	1.18	0.63 to 2.21	.599
	Other	29	1.02	0.13 to 7.96	.984
OS	White	308	0.98	0.42 to 2.32	.969
	Other*		—

NOTE. Tamoxifen + ovarian function suppression is the reference group for all comparisons. A hazard ratio (HR) > 1 indicates improved outcome for tamoxifen + ovarian function suppression (ie, higher risk for tamoxifen alone arm). Adjusted for age (≤ 40, 41-50, ≥ 51 years), tumor size (< 1, 1-2, > 2 cm), hormone receptor (progesterone receptor (PgR) positive or PgR negative/PgR unknown), and most extensive surgery (breast-sparing procedure or mastectomy).

Abbreviations: DFS, disease-free survival; OS, overall survival.

^*Not computable (zero deaths in this group).